top of page
KRAS Cancer News & Updates
Essential Guide to Cancer Biomarkers For Cancer Patients
Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus.
Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference.
Biomarkers provide the insights as to what is driving the cancer.
KRAS Kickers
3 days ago
NEW combination trial arm of RMC-9805 plus RMC-6236
Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...
fireflyannf
Apr 7
Black Diamond trial of BDTX-4933
A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...
fireflyannf
Apr 7
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
" Phase 2 study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with...
fireflyannf
Apr 7
Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
PHASE 1 trial: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS At MD...
fireflyannf
Apr 7
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors
Phase 1 trial, 230 patients Trial opened April 2024 in Australia Expanded to US Locations in September 2024  “ Brief Summary This is a...
fireflyannf
Apr 7
PROSPER trial for KRAS G12C mutations
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)  Phase 1/2 - 403 patients to enroll Opened in...
fireflyannf
Apr 7
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
"This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK),...
fireflyannf
Apr 7
Evaluation of RMC-6236 in Subjects With Advanced Solid Tumors Harboring Specific Mutations in KRAS
Phase 1 trial Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumors Enrollment into...
fireflyannf
Apr 7
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
"Brief Summary Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as...
fireflyannf
Apr 7
BREAKER-101 trial - Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors
“First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in...
fireflyannf
Apr 7
Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic, colorectal and non-small cell lung cancer
ESMO24 abstract 608O - Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in...
fireflyannf
Mar 30
SPARK study: Studying Pathways of Resistance in KRAS-12C driven Cancers
Brief Summary “Up to 250 patients from anywhere in the United States can remotely consent and participate  to have plasma drawn locally...
fireflyannf
Oct 13, 2024
Revolution Medicines: RMC-6236 Pancreatic Cancer Update to Support Pivotal Phase 3 Trial
Rev Med reports out on the 46% of the pancreatic cancer patients who were enrolled in NCT05379985 (54% of patients are NSLC or other...
fireflyannf
Jul 24, 2024
Roller Coaster Ride with lung cancer Kristi C.
Kristi shares with others about her KRAS lung cancer diagnosis and experience with clinical trials.
C Schlatt
Sep 16, 2022
Essential Guide to Cancer Biomarkers For Cancer Patients
Need to know what mutation is driving the cancer bus. It's different than noise from the back of the bus.
Biomarkers testing tells us what to Aim for as the cancer driver, not the background noise. Taking out the cancer driver can make the difference.
Biomarkers provide the insights as to what is driving the cancer.
NEW combination trial arm of RMC-9805 plus RMC-6236
Changes to KRAS G12D trial - July 23, 2024 The monotherapy arm of RMC-9805 - RAS(ON) inhibitor now includes info on the combination arm...
Black Diamond trial of BDTX-4933
A Phase 1 Study of BDTX-4933 in Patients With BRAF and Select RAS/MAPK Mutation Positive Cancers Brief Summary: "BDTX-4933-101 is a...
bottom of page